恆指吐逾百點曾考驗25,800 港交所/美團/阿里巴巴跌逾2%-3% 石油及藥股逆升
財新香港8月PMI由前值51.3,急升至53.3創七年半高。不過,恆指繼昨天逼近26,400無以為繼後,今早扭四連升,考驗20天線(25,864),最多回吐278點,低見25,811獲承接,現報25,953,回吐136點或0.5%,成交額769億元。
藍籌股個別發展,國家主席習近平促設立北京證券交易所,港交所(00388.HK)繼昨天升至514元遇阻,今天股價一舉跌破10天、20天及50天線(490.3-495.8元),最低見483元,現報485.6元,回吐2.6%。建行(00939.HK)失守50天線(5.64元),報5.62元,反覆續跌0.7%。相反,下周一起正式遭剔除藍籌的交行(03328.HK)回升2%報4.54元,股價重越20天線。
新經濟股騰訊(00700.HK)繼昨天高見510元遇阻收市未能企穩50天線後,今早股價扭三連升,反覆低見481.6元,現報489.2元,回吐1.4%。美團(03690.HK)回升受制百天線,今早股價扭四連升,最低見239.4元,現報245.8元,回吐3.1%。阿里巴巴(09988.HK)今早低見164元,現報165.3元,回吐3.3%。
比亞迪(01211.HK)及吉利(00175.HK)反覆回吐2.1%及1.4%,報256.8元及27.7元,前者失守10天及20天線。
貼價漲「三桶油」升逾2%-4%,中海油(00883.HK)、中石油(00857.HK)及中石化(00386.HK)分別高見7.88元、3.54元及3.98元,前者股價重越10天線(7.79元),後者股價升破百天線(3.9元)。中信股份(00267.HK)高見10.1元為去年1月以來最高,現報10.04元,續升2.5%。
藥明生物(02269.HK)、石藥(01093.HK)、中生製藥(01177.HK)及阿里健康(00241.HK)反覆續升逾2%,分別報116.3元、10.1元、6.86元及13.64元,後者股價升破50天線(13.44元)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.